{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:07:11Z","timestamp":1768734431305,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-SHINKOGYOSEI-SHITEI-003"],"award-info":[{"award-number":["H29-SHINKOGYOSEI-SHITEI-003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:18:57Z","timestamp":1559121537000},"page":"3588-3597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan"],"prefix":"10.1016","volume":"37","author":[{"given":"Shu-ling","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-8213","authenticated-orcid":false,"given":"Xerxes","family":"Seposo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.006_b0005","series-title":"Principles and practice of infectious diseases","first-page":"1731","article-title":"Varicella zoster virus","author":"Whitley","year":"2015"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.006_b0010","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2019.05.006_b0015","unstructured":"Varicella and Herpes Zoster vaccines. WHO position paper position paper, June 2014. Wkly Epidemiol Rec 2014 20;89(25):265\u201387."},{"issue":"10","key":"10.1016\/j.vaccine.2019.05.006_b0020","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/1346-8138.13334","article-title":"Relationship between prior knowledge about herpes zoster and the period from onset of the eruption to consultation in patients with herpes zoster","volume":"43","author":"Miyachi","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.vaccine.2019.05.006_b0025","unstructured":"GSK press release. Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over. London, UK. 23 March 2018. <https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over\/> [last accessed 2018 Oct 15]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.006_b0030","doi-asserted-by":"crossref","first-page":"ofx007","DOI":"10.1093\/ofid\/ofx007","article-title":"Miyazaki Dermatologist Society. Herpes zoster and recurrent herpes zoster","volume":"4","author":"Shiraki","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2019.05.006_b0035","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/jmv.21599","article-title":"Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture","volume":"81","author":"Toyama","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.05.006_b0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.11150\/kansenshogakuzasshi.85.161","article-title":"Varicella vaccine potency and stability during transport and delivery","volume":"85","author":"Kamiya","year":"2011","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.vaccine.2019.05.006_b0045","unstructured":"Record of proceedings of the committee of Immunisation and Vaccine, Health Science Council, Ministry of Health, Welfare and Labour of Japan; 2016. June 22. [Japanese] <http:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000130809.html> [last accessed 2019 Feb 28]."},{"issue":"24","key":"10.1016\/j.vaccine.2019.05.006_b0050","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.vaccine.2017.04.046","article-title":"Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan","volume":"35","author":"Hoshi","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.006_b0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"33","key":"10.1016\/j.vaccine.2019.05.006_b0060","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.006_b0065","unstructured":"Ikeda S. [Research guidelines on the evaluation of the cost-effectiveness of vaccination of Japan (Seshyu no Hiyoutaikouka no Hyouka ni Kansuru Kenkyu Gaidorain)]. Report of Research Grant for Research on Emerging and Re-emerging Infectious Diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan. March 2017. [Japanese] <https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000184902_1.pdf> [last accessed 2019 Feb 28]."},{"key":"10.1016\/j.vaccine.2019.05.006_b0070","first-page":"41","article-title":"Dealing with productivity losses in cost-effectiveness evaluations of vaccination","volume":"66","author":"Igarashi","year":"2017","journal-title":"J Natl Inst Public Health"},{"key":"10.1016\/j.vaccine.2019.05.006_b0075","unstructured":"TreeAge Pro 2015, R1.0. TreeAge Software, Williamstown, MA; software available at <https:\/\/www.treeage.com>."},{"key":"10.1016\/j.vaccine.2019.05.006_b0080","unstructured":"Ministry of Internal Affairs and Communications. Population estimates of Japan. Statistics Bureau, Tokyo; 2002."},{"key":"10.1016\/j.vaccine.2019.05.006_b0085","unstructured":"Watanabe D. [Sinki Taijouhousin Sabu Unito Wakutin (New shingles subunit vaccine)] Infectious Agents Survellance Report (IASR). 2018;142-4. [Japanese] <https:\/\/www.niid.go.jp\/niid\/ja\/allarticles\/surveillance\/2433-iasr\/related-articles\/related-articles-462\/8237-462r09.html> [last accessed 2019, March 1]."},{"key":"10.1016\/j.vaccine.2019.05.006_b0090","unstructured":"Record of proceedings of the committee of Immunisation and Vaccine, Health Science Council, Ministry of Health, Welfare and Labour of Japan; 2017. Feburary 10. [Japanese] <http:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000130809.html> [last accessed 2019 Feb 28]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.006_b0095","first-page":"20","article-title":"[A nationwide survey of PPSV23 vaccine coverage rates and their related factors among the elderly in Japan, 2016]","volume":"65","author":"Murakami","year":"2018","journal-title":"Nihon Koshu Eisei Zasshi"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.006_b0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13555-018-0236-3","article-title":"The potential public health impact of herpes zoster vaccination of people aged \u2265 50 years in Japan: results of a markov model analysis","volume":"8","author":"Watanabe","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2019.05.006_b0105","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.05.006_b0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2188\/jea.JE20140210","article-title":"Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study","volume":"25","author":"Takao","year":"2015","journal-title":"J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.006_b0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/1346-8138.13639","article-title":"Burden of herpes zoster and post-herpetic neuralgia in Japanese adults 60 years of age or older: results from an observational, prospective, physician practice-based cohort study","volume":"44","author":"Sato","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.vaccine.2019.05.006_b0120","unstructured":"Ministry of Health, Labour and Welfare. Vital statistics of Japan 2015. Health and Welfare Statistics Association, Tokyo. [Japanese] <http:\/\/www.e-stat.go.jp\/SG1\/estat\/List.do?lid=000001158448> [last accessed 2018 Oct 15]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.006_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-017-0581-5","article-title":"Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in japanese adults aged 60 years or older: results from a prospective, observational cohort study","volume":"38","author":"Mizukami","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.006_b0130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J Dermatol"},{"issue":"16","key":"10.1016\/j.vaccine.2019.05.006_b0135","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.vaccine.2016.02.058","article-title":"Universal varicella vaccine immunization in Japan","volume":"34","author":"Yoshikawa","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.006_b0140","unstructured":"Clinical Trial gov Identifier: NCT02114333)], official title: A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ\/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients."},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.006_b0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.006_b0150","unstructured":"Prosser LA. Economic evaluation of vaccination for prevention of herpes zoster and related complications. Presentation to the advisory committee on immunization practices october 25th, 2017. <https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-10\/zoster-03-prosser.pdf> [last accessed 2018 Oct 15]."},{"issue":"22","key":"10.1016\/j.vaccine.2019.05.006_b0155","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.006_b0160","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.006_b0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.05.006_b0170","unstructured":"National pharmaceutical services. Drug update: April 2018. <https:\/\/www.pti-nps.com\/nps\/index.php\/drug-update-november-2017\/> [last accessed 2019 Feb 27]."},{"key":"10.1016\/j.vaccine.2019.05.006_b0175","unstructured":"CDC vaccine price list. <https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html> [last accessed 2019 Feb 27]."},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.006_b0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40801-017-0119-4","article-title":"Economic burden of herpes zoster and post-herpetic neuralgia in adults 60 years of age or older: results from a prospective, physician practice-based cohort study in Kushiro, Japan","volume":"4","author":"Nakamura","year":"2017","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.vaccine.2019.05.006_b0185","series-title":"Methods for the economic evaluation of health care programmes","year":"2015"},{"key":"10.1016\/j.vaccine.2019.05.006_b0190","unstructured":"Record of proceedings of the committee of cost-effectiveness, Central Social Insurance Medical Council, Ministry of Health, Welfare and Labour of Japan; 2017. March 15. [Japanese] <http:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-chuo.html?tid=128159> [last accessed 2018 Oct 15]."},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.006_b0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2019.05.006_b0200","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE: London; 2013."},{"key":"10.1016\/j.vaccine.2019.05.006_b0205","unstructured":"Net Monetary Benefit [online]. York; York Health Economics Consortium; 2016. <http:\/\/www.yhec.co.uk\/glossary\/net-monetary-benefit\/> [last accessed 2018 Oct 15]."},{"issue":"22","key":"10.1016\/j.vaccine.2019.05.006_b0210","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2019.05.006_b0215","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.006_b0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2019.05.006_b0225","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.006_b0230","doi-asserted-by":"crossref","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:46Z","timestamp":1759401226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":46,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19305997"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}